• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study.

作者信息

Lytvyn Yuliya, Zaaroura Hiba, Mufti Asfandyar, AlAbdulrazzaq Shaikhah, Yeung Jensen

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

JAAD Int. 2021 Jul 8;4:49-51. doi: 10.1016/j.jdin.2021.05.003. eCollection 2021 Sep.

DOI:10.1016/j.jdin.2021.05.003
PMID:34409392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8362285/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f75/8362285/0a3c3eab7366/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f75/8362285/0a3c3eab7366/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f75/8362285/0a3c3eab7366/gr1.jpg

相似文献

1
Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study.古塞库单抗在斑块状银屑病患者中的药物留存率：一项为期2年的回顾性多中心研究。
JAAD Int. 2021 Jul 8;4:49-51. doi: 10.1016/j.jdin.2021.05.003. eCollection 2021 Sep.
2
Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.转换为古塞库单抗后红皮病型银屑病患者的治疗反应
Dermatol Ther (Heidelb). 2021 Feb;11(1):301-306. doi: 10.1007/s13555-020-00480-x. Epub 2021 Feb 3.
3
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
4
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6.
5
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.古塞库单抗与司库奇尤单抗治疗中重度银屑病（ECLIPSE）：一项 3 期随机对照临床试验的结果。
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
6
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.评估古塞库单抗：一种用于治疗斑块状银屑病的抗白细胞介素-23抗体。
Drug Des Devel Ther. 2019 Jun 18;13:1993-2000. doi: 10.2147/DDDT.S137588. eCollection 2019.
7
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.古塞库单抗治疗银屑病：III期试验综述
Dermatol Ther (Heidelb). 2017 Sep;7(3):281-292. doi: 10.1007/s13555-017-0187-0. Epub 2017 Jun 21.
8
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，依奇珠单抗与古塞库单抗的头对头比较：一项随机双盲试验的24周疗效和安全性结果。
Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25.
9
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.古塞单抗（一种针对 IL-23 的 mAb）可使中重度斑块状银屑病患者获得临床和分子应答。
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
10
Guselkumab in the treatment of moderate-to-severe plaque psoriasis.古塞奇尤单抗治疗中重度斑块状银屑病。
Immunotherapy. 2020 Apr;12(6):355-371. doi: 10.2217/imt-2020-0040. Epub 2020 Apr 21.

引用本文的文献

1
Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation.在资源有限的国家中，对于中重度斑块型银屑病且对白细胞介素-17 抑制剂治疗失败的患者，采用序贯白细胞介素-17 抑制剂治疗：一项经济评价。
PLoS One. 2024 Aug 9;19(8):e0307050. doi: 10.1371/journal.pone.0307050. eCollection 2024.
2
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.银屑病中白介素-17 和白介素-23 抑制剂的药物生存：系统评价和荟萃分析。
Drugs. 2024 May;84(5):565-578. doi: 10.1007/s40265-024-02028-1. Epub 2024 Apr 17.
3

本文引用的文献

1
Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series.成年银屑病患者中古塞库单抗给药间隔优化：一项回顾性多中心病例系列研究。
J Am Acad Dermatol. 2020 Dec;83(6):1813-1814. doi: 10.1016/j.jaad.2020.04.025. Epub 2020 Apr 11.
2
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.司库奇尤单抗和依奇珠单抗治疗中重度斑块型银屑病的药物生存情况。
J Am Acad Dermatol. 2019 Jul;81(1):173-178. doi: 10.1016/j.jaad.2019.03.048. Epub 2019 Mar 23.
3
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
古塞库单抗治疗中度至重度银屑病的长期疗效和安全性：一项3年真实世界回顾性研究
Psoriasis (Auckl). 2022 Jul 14;12:205-212. doi: 10.2147/PTT.S372262. eCollection 2022.
4
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.真实世界数据显示，古塞库单抗治疗斑块状银屑病患者的药物生存期较长。
Acta Derm Venereol. 2022 Aug 11;102:adv00755. doi: 10.2340/actadv.v102.685.
5
Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.培戈利珠单抗治疗中重度银屑病的疗效：来自加拿大两个中心的真实世界数据。
J Cutan Med Surg. 2022 May-Jun;26(3):267-273. doi: 10.1177/12034754221078203. Epub 2022 Feb 8.
古塞库单抗治疗乌司奴单抗应答不足的银屑病患者的疗效和安全性：随机、双盲、III 期 NAVIGATE 试验结果。
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
4
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
5
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.